Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

By Hiroyuki Nishimura, Taku Okazaki, Yoshimasa Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, Akira Mizoguchi, H. Hiai, N. Minato and 1 more. Science, 2001

1,850 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/9d625eacb9c439e29dd01aa715ea8239c4810024

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Tasuku Honjo
2. Taku Okazaki

In Radiology, Nuclear Medicine and Imaging

1. C. June
2. Tasuku Honjo
3. Rafi Ahmed
4. Taku Okazaki
5. M. Glennie

Citations in the corpus

• Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy (2014, methodology): “Splenocytes were restimulated with the following synthetic HY-specific peptides: (i) Uty: the immunodominant Db–restricted HY-derived peptide corresponding to amino acids 245 to 253 (WMHHNMDLI) of the Uty gene product; (ii) Dby: the immunodominant I-Ab–restricted (NAGFNSNRANSSRSS) HYderived peptide;”
• Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice (2003, background): “We have recently shown that PD-1-deficient BALB/c mice develop DCM, which is dependent on the presence of mature T and/or B lymphocyte”
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells (2004, background): “Moreover, PD-1-deficient mice develop autoimmune syndromes that are potentiated on certain genetic backgrounds (17, 18).”
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012, background): “Metastases 56 23/24 (96) 1/24 (4) 7/32 (22) 25/32 (78) <0.”
• The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice (2003, background): “Given the autoimmune phenotypes of PD-1–deficient mice and other in vitro data (7, 8), it appears that the PD-1 pathway is inhibitory.”
• Immunostimulatory monoclonal antibodies for cancer therapy (2007, background): “The phenotype of PD-1-null mice is characterized by cell-mediated organ-specific autoimmunit”
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. (2005, background): “PD-1deficient mice develop systemic and organ-specific autoimmune diseases (18, 19).”